#	Pagina
attuale pagina	/open-h2020/projects/223855/index.html

Opendata, web and dolomites

AGLYC SIGNED

The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia

Total Cost €

EC-Contrib. €

Partnership

Views

AGLYC project word cloud

Explore the words cloud of the AGLYC project. It provides you a very rough idea of what is the project "AGLYC" about.

bn 2017 off sales aglyc ivd pharmaceutical damage living model october sensitivity glycardial national diagnosis round represented diseases reducing 64 gt plan ischemia cvd advantages morbidity tests founded lab prevent detecting heart globe event valued vitro closed vision progression estimate cardiac total la lives acute device de medical global death cagr ebitda irreversible europeans demonstrates santa smei 87 cover iccc 86 93 23 council tissue necrosis disease hospital 49 ir laboratory absence events expenses ischemic 98 pau spin society sant accounting successful either 15 65 diagnostic projected company 2023 medtech mins 2015 cardiovascular patients effectiveness market first almost spanish sublicense completion creu detection 31 business 2 nearly competitive diagnostics deaths 166 onset 02

Project "AGLYC" data sheet

The following table provides information about the project.

Coordinator	GLYCARDIAL DIAGNOSTICS, SL Organization address address: CALLE BALDIRI REIXAC 48 - PLANTA 1 PUERTA B04 PARC CIENTIFIC DE BARCELONA TORRE R city: BARCELONA postcode: 8028 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	2˙727˙139 €
EC max contribution	1˙908˙997 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2019
Duration (year-month-day)	from 2019-03-01 to 2021-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	GLYCARDIAL DIAGNOSTICS, SL GLYCARDIAL DIAGNOSTICS, SL Organization address address: CALLE BALDIRI REIXAC 48 - PLANTA 1 PUERTA B04 PARC CIENTIFIC DE BARCELONA TORRE R city: BARCELONA postcode: 8028 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	coordinator	1˙908˙997.00

Map

Project objective

Cardiovascular diseases (CVD) are the leading cause of death/morbidity across the globe, accounting for 31% of all deaths in 2015. In the same year almost 49 m Europeans were living with CVD. Early detection of ischemia is essential to prevent the progression of heart damage and the irreversible tissue damage (necrosis) that can lead to heart failure.

AGLYC is an IVD lab-based test for the early detection of ischemia (15 mins event onset) in the absence of the irreversible necrosis of the tissue. AGLYC demonstrates a 98% sensitivity in detecting the presence of ischemic heart disease. Our main competitive advantages are high sensitivity, early detection of ischemia, and cost effectiveness.

The global in vitro diagnostics (IVD) market was valued at $64.02 bn in 2017 and is projected to reach $87.93 bn by 2023, at a CAGR of 5.2%. The laboratory diagnostic test (lab-based) market represents 86% of the total diagnostic testing market. Specifically, the market for lab tests related to acute cardiac ischemic events represented about $166 m in total sales in 2015. We have estimated a lab-based target market of >70 m patients.

Our main business model will be a sublicense model based on the development of a laboratory-based test that we will develop and then sublicense to either a medical device company (MedTech) or to a pharmaceutical company. With this model and the successful completion of the SMEI phase 2 we estimate an EBITDA of around €23 m.

The company closed a first funding round of €2.4 m on October 2017 to cover nearly 65% of the expenses of the development plan. GlyCardial Diagnostics, S.L. was founded in 2017 as a spin-off of the ICCC- IR-Hospital de la Santa Creu i Sant Pau and the Spanish National Research Council with the focus of developing a novel IVD test for cardiac ischemia. Our vision is to improve the early diagnosis of cardiac ischemic events, reducing the impact of the disease on patients’ lives and society as a whole.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AGLYC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AGLYC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont